Therefore, we assessed the effect of combination treatment on T-helper lymphocytes (CD4+), cytotoxic lymphocytes (CD8+), activated lymphocytes (Granzyme B+), and antitumor macrophages (CD86 positive M1 type macrophages) infiltrating tumor tissue (Fig. 5). The gene discussed is CD4; the disease is neoplasm.